MFP-Fluorides for Osteoporosis


Since 1960, many clinical studies on the use of Fluoride to treat osteoporosis have been reported, with conflicting results, such that general worldwide acceptance of Fluoride Therapy has not been forthcoming. Nevertheless, the unique stimulating action of Fluoride on bone formation has provided the impetus for continued research and finally, in 1995, a breakthrough was achieved when it was discovered that a very low,1 slow-dosage provides complete safe protection against vertebral fractures in mild-moderate osteoporotic patients.

In previous studies, patients had usually absorbed two-to-four times as much fluoride per day for periods of several years, resulting in daily high peak blood levels and toxic retention of fluoride by the bones. Furthermore, in the past, patient populations have included severe osteoporotics who have lost such excessive amounts of bone structure that an inadequate framework exists on which to build new bone. This accounts for the failure of bone-former stimulants like Fluoride in this type of patient.

The preferred source of the new slow-fluoride regimen is MFP (Disodium-monofluorophosphate), because MFP unlike sodium fluoride (NaF) is very compatible with concomittant calcium supplements and dietary calcium which are essential for successful results. Furthermore, MFP is better tolerated and therefore its usage is more conducive to patient compliance. These features of slow MFP were recognized several years ago and have resulted in the granting of worldwide patents, which have now become available for licensing or sale to appropriate pharmaceutical marketers.

1. The biodosage (bioavailable or absorbed dosage) was found to be only 5-10 mgF per day (A quart of fluoridated drinking water contains only 1 mgF). Inspired the safety slogan: "go low and slow to get no woe."

2. "There is no medication like fluoride, when properly used, which is able to increase lumbar BMD and to prevent further crush fractures without systemic side effects in osteoporosis type I." (Nagant, 1996, p.249)